JP2022553077A - Ｍｅｔｔｌ３モジュレーター - Google Patents

Ｍｅｔｔｌ３モジュレーター Download PDF

Info

Publication number
JP2022553077A
JP2022553077A JP2022523855A JP2022523855A JP2022553077A JP 2022553077 A JP2022553077 A JP 2022553077A JP 2022523855 A JP2022523855 A JP 2022523855A JP 2022523855 A JP2022523855 A JP 2022523855A JP 2022553077 A JP2022553077 A JP 2022553077A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
halo
membered
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553077A5 (enExample
Inventor
トーマス・アンドリュー・ウィン
ブライアン・ルイス・ホダウス
ポーラ・アン・ボリアック－ショーディン
アーネスト・アレン・シックミアー
ジェームス・エドワード・ジョン・ミルズ
ロバート・エイ・コープランド
ブライアン・アンドリュー・スパーリング
マシュー・エイチ・ダニエルズ
アンドリュー・スチュアート・タスカー
ケネス・ダブリュ・ダンカン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accent Therapeutics Inc
Original Assignee
Accent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accent Therapeutics Inc filed Critical Accent Therapeutics Inc
Publication of JP2022553077A publication Critical patent/JP2022553077A/ja
Publication of JP2022553077A5 publication Critical patent/JP2022553077A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022523855A 2019-10-21 2020-10-20 Ｍｅｔｔｌ３モジュレーター Pending JP2022553077A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962923936P 2019-10-21 2019-10-21
US62/923,936 2019-10-21
PCT/IB2020/001135 WO2021079196A2 (en) 2019-10-21 2020-10-20 Mettl3 modulators

Publications (2)

Publication Number Publication Date
JP2022553077A true JP2022553077A (ja) 2022-12-21
JP2022553077A5 JP2022553077A5 (enExample) 2023-10-30

Family

ID=73856560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523855A Pending JP2022553077A (ja) 2019-10-21 2020-10-20 Ｍｅｔｔｌ３モジュレーター

Country Status (6)

Country Link
US (1) US20230027361A1 (enExample)
EP (1) EP4048674A2 (enExample)
JP (1) JP2022553077A (enExample)
CN (1) CN115298179A (enExample)
AU (1) AU2020372002A1 (enExample)
WO (1) WO2021079196A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022074391A1 (en) * 2020-10-08 2022-04-14 Storm Therapeutics Limited Compounds inhibitors of mettl3
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物
CN114032311A (zh) * 2021-12-24 2022-02-11 山东大学齐鲁医院 Mettl3在aml化疗耐药性中的应用
EP4477654A4 (en) * 2022-02-11 2026-05-20 Xizang Haisco Pharmaceutical Co Ltd METTL3 INHIBITOR AND COMPOSITION, AND THEIR APPLICATION IN MEDICINE
CN115850280B (zh) * 2022-12-08 2024-07-05 南京康立瑞生物科技有限公司 一种抗病毒药恩替卡韦中间体n4的制备方法
US12091400B2 (en) 2023-01-20 2024-09-17 Epics Therapeutics Piperidine derivatives as METTL3 inhibitors
EP4688768A1 (en) 2023-03-30 2026-02-11 Novalix Novel mettl3 inhibitors and use thereof in therapy
WO2025049624A1 (en) * 2023-08-29 2025-03-06 Purdue Research Foundation Prodrugs of nicotinamide n-methyltransferase (nnmt) inhibitors and uses thereof
WO2025106014A1 (en) * 2023-11-14 2025-05-22 Engine Biosciences Pte. Ltd. Compounds and methods for pkmyt1 inhibition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
JP2018528946A (ja) * 2015-08-26 2018-10-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な６−６二環式芳香環置換ヌクレオシド類似体
WO2019032859A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
WO2019112719A1 (en) * 2017-12-05 2019-06-13 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
WO2020205867A1 (en) * 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528946A (ja) * 2015-08-26 2018-10-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な６−６二環式芳香環置換ヌクレオシド類似体
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2019032859A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
WO2019112719A1 (en) * 2017-12-05 2019-06-13 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
WO2020205867A1 (en) * 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"CAS REGISTRY No．2086772-11-2，2086772-09-8，2086770-91-2", DATABASE REGISTRY, JPN7024003871, 2017, pages 2024 - 8, ISSN: 0005416632 *

Also Published As

Publication number Publication date
WO2021079196A9 (en) 2022-07-14
US20230027361A1 (en) 2023-01-26
WO2021079196A2 (en) 2021-04-29
EP4048674A2 (en) 2022-08-31
CN115298179A (zh) 2022-11-04
AU2020372002A1 (en) 2022-05-26
WO2021079196A3 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
WO2021079196A9 (en) Mettl3 modulators
EP4392414A1 (en) Inhibitors of nlrp3
RU2605096C2 (ru) Пиразолохинолиновое производное
ES2718218T3 (es) Derivados de 4,5,6,7-tetrahidropirazolo[1,5-a]pirazina sustituidos como inhibidores de caseína cinasa 1 D/E
JP2022553376A (ja) Ｍｅｔｔｌ３モジュレーター
EP3157925B1 (en) Imidazo-pyridazine derivatives as casein kinase 1 delta/epsilon inhibitors
EP3145512B1 (en) Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
RS55632B1 (sr) Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2-3-b]pirimidini kao inhibitori janus kinaze
JP7219902B2 (ja) ブルトン型チロシンキナーゼ阻害剤
EA021504B1 (ru) Производные 1-гетероциклил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве модуляторов pde9a
RS59904B1 (sr) Novi derivati hidroksiestara, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
WO2013026025A1 (en) Cyclohexyl azetidine derivatives as jak inhibitors
JP2018514551A (ja) Ｊａｋ阻害剤
KR20150091169A (ko) Syk 저해제로서의 치환된 피리도피라진
WO2022081739A1 (en) Mettl3 modulators
EP2617720B1 (en) Novel cortistatin a analog and use thereof
CN116354992A (zh) 一类pde4抑制剂及其在药物中的应用
WO2019072978A1 (en) MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
CN113880842B (zh) 取代的炔基杂环化合物
WO2022070288A1 (ja) 含窒素二環化合物
EA052733B1 (ru) Ингибиторы nlrp3
TW202327581A (zh) 含氮雙環化合物
CN117486885A (zh) 吡唑并嘧啶类化合物的用途
HK1124609A1 (en) Inhibitors of e1 activating enzyme
HK1124609B (en) Inhibitors of e1 activating enzyme

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250311